ES2083030T3 - Metodo de tratamiento de la inflamacion ocular. - Google Patents

Metodo de tratamiento de la inflamacion ocular.

Info

Publication number
ES2083030T3
ES2083030T3 ES92112716T ES92112716T ES2083030T3 ES 2083030 T3 ES2083030 T3 ES 2083030T3 ES 92112716 T ES92112716 T ES 92112716T ES 92112716 T ES92112716 T ES 92112716T ES 2083030 T3 ES2083030 T3 ES 2083030T3
Authority
ES
Spain
Prior art keywords
treatment
eye inflammation
mammal
inflammation
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92112716T
Other languages
English (en)
Inventor
Prasad Shrikrishna Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Application granted granted Critical
Publication of ES2083030T3 publication Critical patent/ES2083030T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE MUESTRA UN METODO Y COMPOSICION PARA TRATAR INFLAMACION OCULAR EN UN MAMIFERO QUE NECESITA DICHO TRATAMIENTO, E INCLUYE ADMINISTRAR AL MAMIFERO UNA CANTIDAD ANTIINFLAMATORIA DE RAPAMICINA.
ES92112716T 1991-07-25 1992-07-24 Metodo de tratamiento de la inflamacion ocular. Expired - Lifetime ES2083030T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73560491A 1991-07-25 1991-07-25

Publications (1)

Publication Number Publication Date
ES2083030T3 true ES2083030T3 (es) 1996-04-01

Family

ID=24956475

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92112716T Expired - Lifetime ES2083030T3 (es) 1991-07-25 1992-07-24 Metodo de tratamiento de la inflamacion ocular.

Country Status (20)

Country Link
US (1) US5387589A (es)
EP (1) EP0532862B1 (es)
JP (1) JP2568962B2 (es)
KR (1) KR100216768B1 (es)
AT (1) ATE133336T1 (es)
AU (1) AU653415B2 (es)
CA (1) CA2074641C (es)
CZ (1) CZ285660B6 (es)
DE (1) DE69207847T2 (es)
DK (1) DK0532862T3 (es)
ES (1) ES2083030T3 (es)
HK (1) HK1005705A1 (es)
HU (1) HU211218B (es)
IE (1) IE922430A1 (es)
IL (1) IL102414A (es)
MX (1) MX9204381A (es)
NZ (1) NZ243679A (es)
RU (1) RU2048812C1 (es)
SK (1) SK280511B6 (es)
ZA (1) ZA924953B (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514686A (en) * 1991-04-26 1996-05-07 Fujisawa Pharmaceutical Co., Ltd. Use of macrolide compounds for eye diseases
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
KR19990048077A (ko) * 1997-12-08 1999-07-05 전원중 인조대리석 성형품의 제조방법
DK1056454T3 (da) * 1998-02-23 2003-08-18 Fujisawa Pharmaceutical Co Anvendelse af makrolidforbindelser til behandling af glaukom
WO2000003705A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
CA2356382A1 (en) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
RU2187984C2 (ru) * 1999-02-26 2002-08-27 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ лечения воспалительных заболеваний глаза
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
AU777915B2 (en) * 1999-04-30 2004-11-04 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
RU2180822C2 (ru) * 1999-09-28 2002-03-27 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения заболеваний и повреждений передней поверхности глаза
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1319008B1 (en) 2000-09-19 2008-10-15 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
MXPA04001523A (es) 2001-08-22 2004-05-31 Wyeth Corp Dialdehidos de rapamicina.
BR0211986A (pt) 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
US20050043286A1 (en) * 2001-11-19 2005-02-24 Mario Fsadni Use of an ascomycin for the treatment of blepharitis
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
NZ537829A (en) 2002-07-30 2006-09-29 Wyeth Corp Parenteral formulations containing a rapamycin hydroxyester
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
US8163726B2 (en) * 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
ATE352301T1 (de) * 2003-04-22 2007-02-15 Wyeth Corp Antineoplastische zusammensetzungen
RU2232586C1 (ru) * 2003-04-23 2004-07-20 Закрытое Акционерное Общество Производственное Предприятие "Эндо-Фарм-А" Офтальмологическое лекарственное средство и способ лечения заболеваний, патологических состояний и повреждений сетчатой оболочки глаза
RU2242192C1 (ru) * 2003-06-18 2004-12-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Фармацевтическая композиция для лечения воспалительных процессов в заднем отрезке глаза "делипос"
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
RU2240107C1 (ru) * 2003-10-21 2004-11-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Гель для лечения бактериальных конъюнктивитов (варианты)
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
RU2284181C2 (ru) * 2004-11-11 2006-09-27 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Федерального агентства по здравоохранению и социальному развитию (ФГУ "МНТК"МГ"им. акад. С.Н. Федорова Росздрава") Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк"
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
KR20070121754A (ko) * 2005-03-21 2007-12-27 마커사이트, 인코포레이티드 질환 또는 상태의 치료를 위한 약물 송달 시스템
EP1890652B1 (en) 2005-05-13 2017-08-02 Akkolens International B.V. Intra-ocular artificial lens for iris-driven accommodation
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
US20070071754A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Method to ameliorate inflammation
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) * 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
EP2083834B1 (en) 2006-09-13 2017-06-21 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
RU2331408C1 (ru) * 2007-05-31 2008-08-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Глазная мазь
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
WO2009070530A1 (en) * 2007-11-27 2009-06-04 Alcon Research, Ltd. Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE
AU2010233073B2 (en) * 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
US20140255355A1 (en) * 2013-03-07 2014-09-11 Stemnion, Inc. Methods for treating blepharitis
RU2765728C2 (ru) 2016-05-25 2022-02-02 Сантен Фармасьютикал Ко., Лтд. Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком
KR20190025635A (ko) 2016-06-30 2019-03-11 듀렉트 코퍼레이션 데포 제형
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
JP2020507632A (ja) 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
US20230055121A1 (en) 2019-12-26 2023-02-23 Santen Pharmaceutical Co., Ltd. Aqueous suspension composition containing sirolimus or salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
ES2066915T3 (es) * 1989-07-05 1995-03-16 Fujisawa Pharmaceutical Co Composicion liquida acuosa para uso externo.

Also Published As

Publication number Publication date
CZ230792A3 (en) 1993-02-17
JP2568962B2 (ja) 1997-01-08
IL102414A0 (en) 1993-01-14
KR930001913A (ko) 1993-02-22
IE922430A1 (en) 1993-01-27
RU2048812C1 (ru) 1995-11-27
CZ285660B6 (cs) 1999-10-13
ATE133336T1 (de) 1996-02-15
NZ243679A (en) 1997-06-24
SK230792A3 (en) 1996-05-08
CA2074641C (en) 1999-05-04
IL102414A (en) 1996-08-04
EP0532862B1 (en) 1996-01-24
MX9204381A (es) 1993-02-01
SK280511B6 (sk) 2000-03-13
HK1005705A1 (en) 1999-01-22
US5387589A (en) 1995-02-07
CA2074641A1 (en) 1993-01-26
HU9202448D0 (en) 1992-10-28
HUT63763A (en) 1993-10-28
AU653415B2 (en) 1994-09-29
AU2035092A (en) 1993-01-28
EP0532862A1 (en) 1993-03-24
KR100216768B1 (ko) 1999-09-01
JPH05194212A (ja) 1993-08-03
HU211218B (en) 1995-11-28
DE69207847T2 (de) 1996-05-30
DE69207847D1 (de) 1996-03-07
ZA924953B (en) 1993-04-28
DK0532862T3 (da) 1996-02-19

Similar Documents

Publication Publication Date Title
ES2083030T3 (es) Metodo de tratamiento de la inflamacion ocular.
DK1920764T3 (da) Fluprostenolisopropylester til anvendelse i behandling af glaukom og okulær hypertension
DK0646012T3 (da) Sårheling og behandling af fibrotiske sygdomme ved hjælp af TGFbeta-3
BR9304981A (pt) Método de provisao de correçao de visao multifocale lente oftalmica
ES2166381T3 (es) Tratamiento de enfermedades vasculares hiperproliferativas.
ES2075331T3 (es) Inhibicion de la atrofia y de la degradacion proteica muscular en los mamiferos mediante tetraciclinas.
FI970489A7 (fi) Paikallisesti käytettäviä silmälääkekoostumuksia, jotka sisältävät dok sepiinijohdoksia ja soveltuvat allergisten silmäsairauksien hoitoon
PT97785A (pt) Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina
IE810785L (en) Anti-inflammatory ophthalmic composition
DE69202019D1 (de) Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS.
ES2095772T3 (es) Utilizacion de derivados de rifamicina para producir un medicamento destinado al tratamiento de la toxoplasmosis.
DK0479799T3 (da) Sårheling
FR2599156B1 (fr) Iris fixe corrigeant la vue du myope et de l'hypermetrope
ES2069823T3 (es) Tratamiento de la hipertension ocular con una combinacion sinergica ocular.
ES2084771T3 (es) Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.
ATE133337T1 (de) Behandlung des glaukoms mit synergistischer kombination
DE69100171D1 (de) Synergistische kombination zur ophthalmischen verwendung.
ES2089387T3 (es) Tratamiento de la hipertension ocular con la ayuda de una combinacion sinergica.
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
UA10928C2 (uk) Спосіб профілактики гіперхолестериhемії
RU92011328A (ru) Способ лечения поражений роговицы
WO1999065511A3 (en) Composition and method for treatment of pseudomonas infection
CO4340602A1 (es) Estructura perfeccionada para gafas protectoras
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
KR930700109A (ko) 신경 질환 치료용 4,4'-[9h-플루오렌-9-일리덴비스(메틸렌)]-비스피리미딘

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 532862

Country of ref document: ES